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ABSTRACT
Interference between pharmacological substances can cause serious
medical injuries. Correctly predicting so-called drug-drug interac-
tions (DDI) does not only reduce these cases but can also result in
a reduction of drug development cost. Presently, most drug-related
knowledge is the result of clinical evaluations and post marketing
surveillance; resulting in a limited amount of information. Existing
data-driven prediction approaches for DDIs typically rely on a sin-
gle source of information, while using information from multiple
sources would help improve predictions. Machine learning (ML)
techniques are used, but the techniques are often unable to deal
with skew in the data. Hence, we propose a new ML approach for
predicting DDIs based on multiple data sources. For this task we
use 12,000 drug features from DrugBank, PharmGKB, and KEGG
drugs, which are integrated using Knowledge Graphs (KGs). To
train our prediction model, we first embed the nodes in the graph
using various embedding approaches. We found that the best per-
forming combination was a ComplEx embedding method creating
using PyTorch-BigGraph (PBG) with a Convolutional-LSTM net-
work and classic machine learning based prediction models. The
model averaging ensemble method of three best classifiers yields
up to 0.94, 0.92, 0.80 for AUPR, F1-score, and MCC, respectively
during 5-fold cross-validation tests.
KEYWORDS
Drug-drug interactions; Linked data; Knowledge graphs; Graph
embeddings; Conv-LSTM network; Model averaging ensemble.
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1 INTRODUCTION
Drug-drug interactions (DDIs) are (often) preventable causes of
medical injuries that occur when a drug causes a pharmacoki-
netic (PK) or pharmacodynamic (PD) effect on the body when it
is taken together with another drug [41, 46]. They are a common
cause of adverse drug reactions (ADRs) and increased healthcare
costs [9]. The majority of ADRs are caused by unintended DDIs
and occasionally arise through co-prescription of drugs. While it
would be ideal for identifying all possible DDIs during clinical trials,
interactions are frequently reported after the drugs are approved
for clinical use. ADRs are a significant threat to public health, as
shown in a study by Shtar et al. They found that about 6.7% of
hospital readmission occurred because of ADRs with a fatality rate
of 0.32% in the USA in 2014. In that year, as many as 807,270 cases
of serious ADRs were reported in the United States, resulting in
123,927 lost lives [38].
For example, acetylsalicylic acid, commonly known as aspirin,
is a drug used for the treatment of pain and fever due to various
causes. This medicine has both anti-inflammatory and antipyretic
effects, which inhibits platelet aggregation and is used in the pre-
vention of blood clots and myocardial infarction. However, the
risk or severity of hypertension can be increased (e.g., negative
drug-drug interaction) when acetylsalicylic acid is combined with
1-benzylimidazole [48]. Predicting potential DDIs reduces unan-
ticipated drug interactions, lowers drug development costs, and
can be used to optimize the drug design process. Thus, the study
of DDIs and ADRs is important in both drug development and
clinical application, especially for co-administered medications.
Since the majority of ADRs occur between pairs of drugs, they
have become the focus of research and clinical studies[46]. To fur-
ther reduce costs and to make the analysis of large amounts of
interactions possible, automated methods for identifying ADRs are
needed. Current approaches involve clinical evaluation of drugs
and post-marketing surveillance. Here, features are extracted from
drug properties such as targets, side-effects, chemical properties,
fingerprint, and drug indications. Then statistical methods and var-
ious supervised ML algorithms (like, e.g., decision tree (DT), Naive
Bayes (NB), k-nearest neighbors (k-NN), logistic regression (LR),
support vector machine (SVM), random forest (RF), and gradient
boosting trees (GBT)) [1] are employed.
Deep learning-based approaches, which can utilize deep features,
are mostly unexplored in the context of DDIs prediction. While
a deep architecture like a convolutional neural network (CNN)
is good at reducing frequency variations by acting as a feature
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extractor [53], a long short-term memory (LSTM) network is good
at temporal modeling and learning orderly sequences from a large
feature space [37]. By combining these two deep architectures,
the convolutional-LSTM(Conv-LSTM) can capture both locally and
globally important drug features which we found to lead to more
accurate DDI predictions [37]. However, the features which have
been traditionally used for these approaches form either a large and
sparse binary matrix or a dense, but small similarity matrix, making
them not ideal for training ML models [8]. Further, an increasing
amount of drug and small molecules data is being generated, and
state-of-the-art approaches still rely on the analysis on a limited
number of data sources only, e.g. DrugBank.
To incorporate multiple data sources, Knowledge Graphs are a
powerful tool, and many biomedical knowledge bases have been
published in this form. In this graph, the nodes represent differ-
ent entities like drugs, diseases, protein targets, substructures, side
effects, and pathways. See e.g., [8, 46] for examples on using Know-
eldge Graphs for DDI prediction. Once the data is in the form of a
Knowledge Graph, we have to extract information from it as fea-
tures for our interaction predictors. To do this, we use embedding
methods which project each node in the graph to a dense vector.
In our work, we consider more sources of DDIs as others. Sci-
entific literature that has predicted DDIs very accurately is often
ignored as ground truth in related work. In this paper, we collected
DDI information from DrugBank [48], the Kyoto Encyclopedia
of Genes & Genomes (KEGG) [23], TWOSIDES [43], and scientific
literature . Then, we created an integrated KG using data fromDrug-
Bank, KEGG drug, PharmGKB [47], and OFFSIDES [43] (excluding
data already in the above mentioned DDI data). To transform the
information from this graph in a format suitable for the prediction
models, we applied different KG embedding techniques. Then, we
trained several ML models as baselines and also performed experi-
ments with the Conv-LSTM model. The key contributions of this
paper can be summarized as follows:
• We have created a dataset with 2,898,937 drug-drug interac-
tion pairs; we believe that this is the largest available.
• We have prepared a large-scale integrated KG about DDIs
with data fromDrugBank, KEGG, OFFSIDES, and PharmGKB
having 1.2 billion triples.
• We have evaluated different KG embeddings techniques with
different settings to train and evaluate ML models.
• We provide a comprehensive evaluation with details analysis
of the outcome and comparison with the state-of-the-art
approaches and baseline models.
• We found that a combined CNN and LSTM network called
Conv-LSTM for predicting DDIs leads to the highest accuracy.
This paper is structured as follows: section 2 discusses related
works with their emerging use cases and potential limitations. Sec-
tion 3 details the proposed approach, including problem formula-
tion, data collections, KG construction, graph embeddings, network
constructions, and training. The results of our experiments can
be found in Section 4, where we also discuss the key findings of
the study. Section 5 provides some explanations of the importance,
highlights the limitations of the study reported, and discusses some
future works before concluding the paper. To avoid confusion, we
use the terms node and drug interchangeably throughout the paper.
2 RELATEDWORK
Till date, DDI prediction is a non-trivial research problem in phar-
macology, and numerous approaches have been proposed to predict
novel DDIs by employing various data sources. Traditional work
relies on in vitro and in vivo experiments and focuses on small
sets of specific drug pairs and had laboratory limitations [15]. With
the emergence of available biomedical data, researchers moved the
focus towards automatically populating and completing biomedical
KGs using large-scale structured databases and text publicly avail-
able [8]. In this scope, the Bio2RDF project made 35 life sciences
datasets as linked open data (LOD) in RDF, in which similar entities
are mapped in different KGs and built large heterogeneous graphs
that also contain biomedical drug-related facts. Although these
approaches made available numerous biomedical KGs, they often
contain incomplete and inaccurate data that impede their applica-
tion in the field of safe medicine development [8]. Lately, ML and
text mining based approaches were used in which pharmacological
similarities of drugs as features are used by regarding the DDIs
prediction task as a link prediction problem.
Different drug similarity metrics are used for inferring DDIs
and their associated recommendations in which LR is trained to
calculate the maximum likelihood by using known DDIs [17]. Sim-
ilarly, DDIs using phenotypic, chemical, biological, therapeutic,
structural, and genomic similarities of drugs are used for predicting
DDIs [9]. Other investigations used pharmacological and graph
qualities between drugs [7] or drug structural similarities and in-
teraction networks incorporating PK and PD knowledge [41] using
LR. Peng et al. [28] developed a Bayesian network, which combines
molecular drug similarity and drug side-effect similarity to predict
the combined effect of drugs. Lately, Andrej K. et al. [24] formulated
the DDIs prediction problem as a binary classification problem to
predict unknown DDIs in 5 arbitrary databases such as DrugBank,
KEGG, NDF-RT, SemMedDB, and Twosides. In these works, super-
vised ML approaches such as DT, NB, k-NN, LR, SVM, RF, and GBT
are mostly used for predicting DDIs from topological and semantic
similarity features. However, feature-based approaches only pre-
dict binary DDIs or those that have been pre-defined in structured
databases and suffer from robustness caused by data sparsity and
vast computation requirements. Similarity-based approaches, in
contrast, do not allow for the calculation of various similarities for
many drugs due to lack of drug information [8].
Several other approaches are proposed using biomedical KGs
and text embedding in which graph embedding is utilized [46]
to overcome issues such as data incompleteness and the sparsity
problem. These learned embeddings are then mostly used for pre-
dicting DDIs. Other works have utilized text mining [15, 31, 42] to
predict and evaluate new DDIs in which either drug-related data
from scientific literature was discovered from large health infor-
mation exchange repository [15] or automated reasoning has been
developed to derive new enzyme-based DDIs from MEDLINE ab-
stracts [42]. With the abundance of biomedical data characterizing
drugs and their associated targets, these methods cannot fuse multi-
ple sources of information and perform inference over the network
of drugs effectively. Therefore, approaches employing KGs embed-
dings and ML-approaches [1, 8, 19, 46] have emerged. In particular,
approaches based on KG embeddings are powerful predictors and
outperform state-of-the-art approaches for inferring new DDIs.
Most of the embedding methods are translation-based; embeddings
are built by treating relations as translations from the head entity
to tail entity. In these methods, the vector embeddings are created
such that h
⊕
r ≈ t where (h, r , t) is a triple of knowledge base
(i.e., the relation r holds between h and t ). For this equation, there
are various options for the
⊕
operator (see e.g., [6, 16, 22]).
With these ideas in mind, the DDIs prediction framework called
Tiresias [1] is proposed in which various sources of drug-related
data and knowledge are used as inputs and provides DDIs pre-
dictions as outputs using an LR classifier. The process starts with
semantic integration of data into a KG describing drug attributes
and relationships with various related entities such as enzymes,
chemical structures, and pathways. The KG is then used to compute
several similarity measures between the drugs in a scalable and
distributed framework. A recent approach called PRD [46] was pro-
posed for predicting DDIs in which graph embedding techniques
such as TransE, TransD, TransH, HolE are employed to overcome
the data incompleteness and sparsity issues [1]. First, a large-scale
drug KG is created from different sources containing biomedical
texts, which are then embedded into a common low dimensional
space into a continuous vector space in which both entities and re-
lations were considered. The learned embeddings are subsequently
used to predict the DDIs using a rich DDI triple encoder (RDTE)
network in which an encoder incorporates the drug-related infor-
mation to obtain the DDI relation representation. The decoder then
reconstructs the embedding vector from the latent representation
and is used to predict the labels for potential DDIs.
However, most translation-based embeddings are limited in their
capacity to model complex and diverse objects, including important
properties of relations, such as symmetric, transitive, one-many,
many-to-one, and many-many relations in KGs [16]. As KG embed-
dings techniques show state-of-the-art performance, generating
quality feature vectors using appropriate embedding methods plays
a significant role. A more recent work [8] employed KG embedding
methods to extract feature vector representation of drugs using
LOD to predict potential DDIs. The effects of DDIs prediction accu-
racy using LR, NB, and RF is also investigated on a single source (the
Bio2RDF DrugBank v4 dataset) with different embedding methods
such as RDF2Vec, TransE, and TransD.
In these approaches, DDIs information extraction from biomedi-
cal texts and drug event reports using text mining (TM) and then in-
ferring DDIs by integrating knowledge from several sources are two
typical steps [24, 32, 43]. Although, the way DDIs are extracted and
the predictions made vary across methods. Numerous approaches
have extracted DDIs from biomedical text using knowledge-rich
and knowledge-poor features [18] or from lexical, syntactical, and
semantic-based features [5]. Other approaches, focus on classifying
DDIs in which an SVM is trained using drug features generated
by similarity measures [4, 33] or by exploiting linguistic informa-
tion [10]. Apart from these, other approaches have employed text
mining for extracting DDIs from a semantically annotated corpus
of documents describing DDIs from DrugBank and MEDLINE ab-
stracts [21, 36].
3 MATERIALS AND METHODS
In this section, we discuss our methods in detail, including the prob-
lem formulation, data collection and integration, KG embeddings,
the Conv-LSTM network construction, and the network training
with hyperparameter optimization. The last step is inferencing DDI
predictions. Figure 1 shows the workflow of the proposed approach.
3.1 Problem formulation
Since DDIs form a complex network in which nodes refer to drugs
and links refer to potential interactions, we approach the DDIs
prediction task as a link prediction problem similar to Shtar et
al. [38]. Given a directed DDI KG as G = (V ,E) in which each edge
e = (u,v) ∈ E represents an interaction between drugs u and v .
Let N denotes the number of drugs, we can define the DDIs matrix
Y ∈ {0, 1}NxN as follows:
yu,v =
{
1, if interaction exits between drugs u and v
0, otherwise. (1)
In eq. (1), a value of 1 for yu,v indicates an existing interaction
between drugs u and v . However, a value of 0 does not mean that
an interaction does not exist in the KG, but it could be that the
interaction has not yet been discovered [38]. Next, we proceed to
DDIs extraction to be followed by KG construction.
3.2 DDIs extraction and KG construction
Since creating an integrated KG and extracting DDIs are the two
most important steps in our approach, we first focus on the data
and knowledge source selection. We constructed our integrated
knowledge graph based on the drugs and drug-target related data
from DrugBank, KEGG drug, and PharmGKB. On the other hand,
OFFSIDES, TWOSIDES, and scientific literature from MEDLINE are
used for finding DDI with enough evidence.
3.2.1 Data collection. At the current time, there is no automated
method or data source available which would provide complete
DDI information. Moreover, the available data is spread over mul-
tiple sources. Therefore, we rely on several sources for collecting
drug-related data. The DrugBank database is a bioinformatics and
cheminformatics resource that combines detailed drug-related infor-
mation, including chemical, pharmacological, and pharmaceutical
data with comprehensive drug target information.
The PharmGKB database1 contains 12,664 drug entries including
2,588 approved small molecule drugs, 1,287 approved biotech drugs,
130 nutraceuticals and over 6,305 experimental drugs [48].The Phar-
mGKB database is a repository for genomic, molecular, and cellular
phenotype data. It also contains clinical information and the impact
of genetic variation on drug response about people who have partic-
ipated in pharmacogenomics research studies. PharmGKB contains
genes, diseases, drugs, and pathways related data as well as detailed
information on 470 genetic variants affecting drug metabolism.
The KEGG databases contain metabolic pathways that are hyper-
linked to metabolite and protein/enzyme information. As of May
2019, KEGG drug database has 10,979 drugs related information
and 501,689 DDIs relations. Finally, the OFFSIDES database, which
contains drug effects mined from adverse event reports based on
1DrugBank v5.1.3, April 02, 2019
Figure 1: workflow of the proposed approach for predicting DDIs
PharmGKB [24, 32], reports 438,802 drug side-effects. From these
sources, we create two datasets: i) the DDI dataset which contains
drug-drug interaction pairs, ii) the knowledge graph which we will
later use as background knowledge for interactions. The latter does
not contain any explicit information about the interactions.
3.2.2 DDI extraction. We employ a semi-supervised approach for
extracting DDIs from the sources mentioned above. We parsed the
DDI information from the provided XML file from DrugBank and
compiled an edge list of drug identifier combinations, which gives us
2,641,889 pairwise DDIs and 2,630,796 unique DDIs spanning 12,112
drugs. Although the KEGG drug database has 10,979 drugs related
and 501,689 DDIs relations, mapping to DrugBank identifiers (IDs)
results in only 58,205 interactions because of missing mappings.
Data from TWOSIDES [44], which is a comprehensive source
of polypharmacy ADRs is also used, but interactions are restricted
to those that cannot be ascribed unambiguously to either drug
alone. Therefore, a collection of the drug pairs for the interacting
compounds built in literature [24] is used in which the PubChem
IDs are used to map TWOSIDES IDs to DrugBank IDs. This way, we
obtained a list of 19,020 DDIs between 351 compounds and 63,473
distinct pairwise DDIs between 645 drugs.
Dhami et al. [14] have identified that a few DDIs reported in the
DrugBank dataset are less evident to interact with each other. We
relied on multi-source evidence for those drug pairs and removed
from the DrugBank DDI list the contradictory ones. Next, Zhang et
Figure 2: extraction of DDIs from different scientific sources
al. [50] reported 145,068 DDIs2 based on label propagation predic-
tion using clinical side-effects. We added these interactions to our
dataset. Finally, Sridhar et al. [40] listed top-ranked ten predictions
for interactions unknown in DrugBank using their PSL model; also,
these pairs were added to our dataset.
2https://astro.temple.edu/~tua87106/ddi.html
Table 1: Statistics of drug-drug interactions
Database/source #DD-interactions
DrugBank 2,630,796
KEGG Drug 40,540
TWOSIDES 82,493
MEDLINE [21], other sources [14, 40, 50, 51] 145,108
Total DDIs 2,898,937
Besides these, we also incorporate the interactions from the 227
MEDLINE abstracts from the DDI corpus [21, 36]. This contributed
327 DDIs based on 1,826 pharmacological substances. Additionally,
some abstracts are also used that are not listed in the DDI corpus
e.g. [14, 40, 50, 51]. for these, the annotation guidelines3 developed
by domain experts were used. A certified pharmacist verified these
annotations. The overall DDI dataset consists of information from
all these sources combined. An overview of the process is shown in
fig. 2 and statistics are collected in table 1 where it should be noted
that duplicates between the data sources are removed to obtain the
final number of interactions (2,898,937).
3.2.3 KGs construction and integration. To create our integrated
knowledge graph, we used data from DrugBank, KEGG, OFFSIDES,
and PharmGKB. Although PharmGKB does not contain DDI infor-
mation, it publishes lexicons of known drug names and synonyms
as well as gene and disease terms and data on genetic pathways.
The dataset is directed at clinicians and researchers. Previously,
Bio2RDF [3] created a large RDF graph that interlinks data from
major databases containing biological entities such as drugs, pro-
teins, pathways, and diseases. Using that data would have been an
option, but the latest version (i.e., v4.0) is already rather outdated.
Instead, we collected the raw DrugBank, KEGG drug, PharmGKB,
and OFFSIDES data from the respective portals and converted them
into RDF using a modified version of Bio2RDF scripts4. Then each
RDF KG was uploaded to a blazegraph RDF triplestore in named
graph5. Then similar to literature [46], federated SPARQL queries
are executed based on the ‘billion triples benchmark’ [35] to extract
selected triples. For our dataset five types of drug-related entities,
namely drugs, genes, proteins, pathways and enzymes, and pheno-
type (i.e., disease, side-effects), are included. Further, nine types of
biological relations are considered: (drug, hasTarget, protein),
(drug, hasTarget, gene), (drug, hasEnzyme, protein), (drug,
hasEnzyme, gene), (drug, hasTransporter, protein), (drug,
hasTransporter, gene6), (protein, isPresentIn, pathway), (gene,
isPresentIn, pathway), and (pathway, isImplicatedIn, phenotype).
Before the extraction, mappings are created based on owl:sameAs
and owl:equivalentProperty axioms in which respective drug
identifiers are mapped to DrugBank IDs as shown in fig. 2. Al-
though genes contain the information needed to make functional
molecules called proteins, we considered relation around genes and
protein distinct, since PharmGKB contains information about both
genes and proteins. The extracted triples are formed the triples
3http://hulat.inf.uc3m.es/DrugDDI/annotation_guidelines_ddi_corpus.pdf
4https://github.com/rezacsedu/DDI-prediction-KG-embeddings-Conv-LSTM/scripts
5Zenodo download link: https://zenodo.org/deposit/3270566
6e.g. Polymorphisms in the ABC drug has transporter gene MDR1
Table 2: Statistics of the data sources
Knowledge graph #Triples #Entities #Relation types
DrugBank 7,740,864 2,116,569 72
KEGG 308,690 107,916 41
OFFSIDES 438,802 875,985 12
PharmGKB 2,793,078 1,583,910 135
Total 11,281,434 4,587,380 260
in our drug KG in the form (subject, predicate, object), indicat-
ing that the subject has the specified relation to the object. Since
this integrated knowledge graph should not contain any explicit
information about drug-drug interactions, there is no informa-
tion in the form of drugbank_vocabulary:ddi-interactor-in and
kegg_vocabulary:Interaction from the DrugBank and KEGG drug
KG, respectively. The number of triples, entities, and relation types
for the individual KGs and the integrated KG are given in table 2.
Next, we will elaborate on how we prepared this data as an input
for our classifiers.
3.3 Knowledge graph embeddings
We used the information of our knowledge graph for predicting
the interaction between each pair of drugs. However, ML classifiers
do typically expect their input as fixed-length vectors. Hence, we
perform a KG embedding procedure to encode the information
from the graph into dense vectors. KG embedding consists of three
steps: representing entities and relations, defining a scoring func-
tion, and learning entity and relation representation [29]. We used
RDF2Vec[34], SimpleIE [25], TransE [6], KGloVe [11], CrossE [52],
and PBG [27] for the KG embeddings. These representations repre-
sent the neighborhood of a node as well as the kind of relations that
exist to the neighboring nodes. Since these methods do not incor-
porate literal information into the embedding, literals are removed
from the KG.
RDF2Vec works by first generating a corpus of text by performing
uniform random walks starting from each entity in the graph [12].
Then, the corpus C of edge-labeled random walks are used as
the input for learning embeddings of each node using the skip-
gram (SG) word2vec [30] model7. From a given a sequence of drug
facts (w1,w2, ...,wn ) ∈ C, the SG model aims to maximize the aver-
age log probability Lp (see eq. (2)) according to the context within
the fixed-size window, in which c represents a context.
Lp =
1
N
N∑
n=1
∑
−c≤j≤c, j,0
logp
(
wn+j |wn
)
(2)
To define p
(
wn+j |wn
)
, we use negative sampling by replacing
logp (wO |wI ) with a function to discriminate target words (wo )
from a noise distribution Pn (w) drawing k words from Pn (w):
logσ
(
v ′⊤wOvwI
)
+
k∑
i=1
Ewi ∼Pn (w )
[
logσ
(
−v ′⊤wivwI
)]
(3)
7Literature [8, 12] have observed better performance using SG than the CBOW model
The embedding of a concept s occurring in corpus C is the vector
vs in eq. (3) derived bymaximizing eq. (2). Besides RDF2Vec, we also
trained TransE embeddings as a representative of the translation-
based KG embedding methods. Here, every entity and relation is
embedded as a low-dimensional vector, where the relations are rep-
resented as the translation from the head entity to tail entity. The
CrossE embedding method, which explicitly simulates crossover
interactions, is also used. Although both general embeddings for
each entity and relation and multiple triple specific embeddings can
be generated using CrossE, we used only the general embeddings.
The SimplE embedding method, which allows two embeddings of
each entity to be learned independently, is also employed. The em-
beddings learned through SimplE are interpretable, which help to
incorporate drug-related background knowledge into the embed-
dings. A reported advantage of SimplE is that it outperforms tensor
factorization techniques, especially for link prediction problems.
Learning the representations in a KG relies on contrasting posi-
tive instances with negative ones. However, KGs typically include
only positive relation instances[39]. A solution to this issue is using
implicit negative evidence in which instances that have not been
observed in the KGs are considered negative. Kotnis and Nastase
et al. [26] employed several negative sampling approaches and ob-
served the impact on the learned embeddings. They found that
the “corrupting positives" method is leading to the best result in a
link prediction task. This corruption produces negative instances
that are closer to the positive ones than those produced through
random sampling. Also several methods which we used in this work
(TransE, CrossE, SimplE, and RDF2Vec) generate negative instances
by corrupting positive samples.
KGloVe [11] has some similarity with RDF2Vec, but uses a differ-
ent technique to identify global patterns for creating vector space
embeddings. First, a co-occurrence matrix is created by person-
alized computing PageRank for each node. Then, this process is
repeated for the graph with all edges reversed. These two matri-
ces are summed together and normalized. Finally, this matrix is
used as an input to the GloVe word embedding algorithm. In this
work, we have only used unbiased walks. As a last model, we train
ComplEx [45] using the PBG implementation [27] because our in-
tegrated KG contains many triples. Technically, ComplEx uses only
the Hermitian dot product for creating embeddings8. The overall
embeddingmethod using ComplEx is arguably simpler but since the
composition of complex embeddings can handle a large variety of
binary relations (among them symmetric and antisymmetric ones)
research has exposed that complex embeddings can outperform
several other models.
We trained the ComplEx embedding model of PBG to i) create
the embeddings faster, scalable for large graphs, and parallelize the
training, and ii) to observe if the embeddings generated by this
model are useful for predicting DDIs. Given these dense represen-
tations, we can now feed the information from the graph into our
machine learning models. To represent the feature vector of a drug
pair, we concatenate the embedding vectors of each drug in the pair
in which the negative samples are generated by corrupting positive
edges by sampling either a new source or a destination for each
existing edge [27].
8Complex counterpart of the standard dot product between real vectors
3.4 Network construction
We train various baseline ML models, which we will use as base-
lines later. Here, we describe the more complex neural network
architecture which gave the best results we obtained. We construct
a so-called Conv-LSTM network [37] by combining both CNN and
LSTM layers as shown in fig. 3. While CNN uses convolutional fil-
ters to capture local relationship values in drug features, the LSTM
network can carry overall relationships from the features extracted
by CNN. The Conv-LSTM has shown good performance on diverse
prediction tasks such as hate speech detection from text [53], for pre-
cipitation nowcasting [37], and for monocular depth prediction [13].
Consequently, it has been able to capture the most significant drug
features in our case.
We extended the Conv-LSTM network proposed in literature [37]
in which each input X1,X2, ...,Xt , cell outputs C1,C2, ...,Ct , hid-
den statesH1,H2....,Ht , and gates it ,ft ,ot of the network are 2D
tensors whose dimensions are spatial dimensions of the drug fea-
tures. Conv-LSTM determines the future state of a certain cell in the
input hyperspace by the inputs and past states of its local neighbors.
This is achieved by using a conv operator in the state-to-state and
input-to-state transitions as represented as follows [37]:
it = σ (Wxi ∗ Xt +Whi ∗ Ht−1 +Wci ◦ Ct−1 + bi ) (4)
ft = σ
(
Wxf ∗ Xt +Whf ∗ Ht−1 +Wcf ◦ Ct−1 + bf
)
(5)
Ct = ft ◦ Ct−1 + it ◦ tanh (Wxc ∗ Xt +Whc ∗ Ht−1 + bc ) (6)
ot = σ (Wxo ∗ Xt +Who ∗ Ht−1 +Wco ◦ Ct + bo ) (7)
Ht = ot ◦ tanh (Ct ) (8)
In the above equations, ∗ denotes the conv operator, and ◦ is the
entrywise multiplication of two matrices of same dimensions. The
second LSTM layer emits an output ‘H ,’ which is then reshaped (i.e.,
flatten) into a feature sequence and fed into fully-connected layers
to predict the DDIs at the next step and as an input at the next
time step. The first layer is the embedding layer, which maps a
drug sample as a ’sequence’ into a real vector domain. Then the
embedding representation with a shape of 100x300 is fed into a 1D
convolutional layer, which has 100 filters and a kernel-size of 4.
The output of each conv layer is then passed to the dropout
layer to regularize learning to avoid overfitting. Intuitively, these
can be thought of as forcing the classifier not to rely on any trivial
individual drug features. The conv layer convolves the input feature
space into a 100x100 representation, which is further down-sampled
by the 1D max pooling layer (MPL) having a pool size of 4 along the
embedding dimension, producing an output of shape 25x100.Where
each of the 25 dimensions can be considered as an ’extracted feature.’
The MPL flattens the output space by taking the highest value in
each timestep dimension, which produces a 1x100 vector containing
drug features that are highly indicative of interest. Contrarily, LSTM
layer treats flattened feature vector’s dimension as timesteps and
outputs 100 hidden units per timestep. Then using a global MPL,
the most influential features are fed into a fully-connected layer
after passing through another dropout layer and finally to a softmax
layer which generates the probability distribution over the classes.
Additionally, we introduce Gaussian noise [49] into each conv,
LSTM, and dense layer to improve the model generalization.
Figure 3: A schematic representation of the Conv-LSTM network, which starts from taking input into an n-dimensional embed-
ding space and passing to both CNN and LSTM layers before getting the vector representation of the most important features
to fed through dense, dropout, Gaussian noise, and Softmax layers for predicting possible drug-drug interactions.
3.5 Network training
Since all the classifiers need both negative and positive samples for
the link prediction problem, previous studies have randomly chosen
negative samples from unknown interactions [40, 50]. However,
setting all the unknown interactions as negative samples creates a
data imbalance issue. Consequently, performance metrics, such as
AUPR and F1-score, get influenced [8]. Other research has tackled
this issue through random undersampling from the unknown inter-
actions at a ratio corresponding to the positive set [9], or inferring
negatives by unsupervised clustering analysis [20].
The open source implementations of PBG9, CrossE10, TransE11,
and SimpleIE12 were used for the KG embedding with the default
parameters provided. On the other hand, the modified version
of KGloVe13 is used, which converged at 400th iteration. While
RDF2Vec was trained using skip-gram by setting window size =
5 with graph walk at depth 5 and 500 walks per entity. Each em-
bedding methods is employed by setting the dimension of the fea-
ture vector to 300 by varying negative samples. By filtering out
the drugs that have no calculated feature vector, we were able to
extract the features for 12,439 drugs out of 12,664 drugs. The em-
beddings generated by RDF2Vec, TransE, PBG, KGloVe, CrossE,
and SimpleIE are then used to train the Conv-LSTM network for
the link prediction similar to [2], in which we aim to estimate
the probability that a relation or link with label l exists between
vertices v1 and v2 given their vector representation, V (v1) and
V (v2) : p(v1,v2, l) ∈ E | ⟨V (v1) ,V (v2)⟩.
L =
∑
i, j ∈Y
−yi, j log yˆi, j −
(
1 − yi, j
)
log
(
1 − yˆi, j
)
(9)
First-order gradient-based optimization techniques Adam, Ada-
Grad, RMSprop, and AdaMax with varying learning rates and dif-
ferent batch sizes are used to learn model parameters, which tries
9https://github.com/facebookresearch/PyTorch-BigGraph
10https://github.com/wencolani/CrossE
11https://github.com/xjdwrj/TransE-Pytorch
12https://github.com/baharefatemi/SimplE
13https://github.com/miselico/globalRDFEmbeddingsISWC
to optimize the binary cross-entropy loss eq. (9). The hyperpa-
rameters optimization is done based on random search and cross-
validation in which the model is trained on a batch size of 128
wherein each of 5 runs 70% of the data is used for the training,
30% for evaluating the network, and 10% from the training set is
randomly used for the validation.
4 EXPERIMENTS
The evaluation code14 was written in Python.The software stack
consists of Scikit-learn, PyTorch, and Keras with the TensorFlow
backend. The network training is carried out on an Nvidia GTX
1080i GPU with CUDA and cuDNN enabled. We also trained LR,
KNN, NB, SVM, RF, and GBT as ML baseline models. Similar to
Conv-LSTM network, we perform the hyperparameter optimiza-
tion for these classifiers through a random search and 5-fold cross-
validation tests. For the experiment, 80% of the data is used for the
training using 5-fold cross-validation and evaluate the optimized
model on 20% held-out data in which the best hyperparameters
were produced through a random search. Although AUC score is
used commonly as a performance metric in previous studies, lit-
erature has emphasized that it might not be sufficiently accurate
for imbalanced data [8, 24]. Therefore, we used the area under
the precision-recall curve (AUPR), and Matthias correlation coef-
ficient (MCC) along with the AUC and F1-score to measures the
performance of the classifiers. Finally, we use the model averaging
ensemble (MAE) of top-3 models to report the final prediction.
4.1 Analysis of DDIs predictions
Table 3 summarizes the results of the prediction task based on
different embedding methods. A general observation is that the
Conv-LSTMmodel outperformed all baseline models, in the best case
resulting in an AUPR of 0.93. Also, overall LR, NB, KNN, and SVM
models performed worst. Although these algorithms are intrinsi-
cally simple, have low variance, and less prone to over-fitting, fea-
ture selector based on these may be discriminating drug-related fea-
tures very aggressively, which forces these classifiers to lose some
14Source code: https://github.com/rezacsedu/DDI-prediction-KG-embeddings-Conv-LSTM
Table 3: Prediction comparison across embedding methods.
* signifies the embedding method giving best accuracy.
Embedding Model AUPR F1-score MCC
ComplEx*
LR 0.74 0.72 0.53
NB 0.73 0.70 0.55
SVM 0.80 0.81 0.69
KNN 0.69 0.71 0.51
GBT 0.88 0.85 0.72
RF 0.91 0.92 0.75
Conv-LSTM 0.93 0.91 0.79
MAE 0.94 0.92 0.80
SimpleIE
LR 0.76 0.72 0.59
NB 0.73 0.72 0.55
SVM 0.80 0.81 0.66
KNN 0.73 0.73 0.53
GBT 0.87 0.86 0.74
RF 0.89 0.88 0.77
Conv-LSTM 0.91 0.90 0.78
MAE 0.92 0.91 0.79
KGloVe
LR 0.75 0.73 0.54
NB 0.72 0.71 0.53
SVM 0.78 0.79 0.68
KNN 0.71 0.69 0.53
GBT 0.87 0.85 0.71
RF 0.89 0.86 0.73
Conv-LSTM 0.87 0.89 0.74
MAE 0.89 0.90 0.75
TransE
LR 0.72 0.71 0.57
NB 0.69 0.70 0.51
SVM 0.75 0.74 0.64
KNN 0.63 0.59 0.49
GBT 0.83 0.82 0.69
RF 0.84 0.85 0.71
Conv-LSTM 0.86 0.87 0.73
MAE 0.87 0.88 0.74
CrossE
LR 0.65 0.68 0.47
NB 0.70 0.71 0.50
SVM 0.72 0.73 0.55
KNN 0.69 0.66 0.52
GBT 0.81 0.82 0.65
RF 0.82 0.83 0.66
Conv-LSTM 0.85 0.84 0.67
MAE 0.86 0.85 0.69
RDF2Vec
LR 0.65 0.68 0.47
NB 0.69 0.70 0.48
SVM 0.71 0.72 0.52
KNN 0.67 0.64 0.50
GBT 0.79 0.80 0.61
RF 0.80 0.81 0.62
Conv-LSTM 0.83 0.82 0.67
MAE 0.84 0.85 0.69
Figure 4: ROC curves of cross-validated Conv-LSTM model
useful drug features which result in worse performance. Among the
tree-based classifiers, RF performs the best, showing an F1-score
of 0.91, which is the best among the ML baselines. The model av-
eraging ensemble of top-3 models (i.e., GBT, RF, and Conv-LSTM)
boosts the performance by 1.5%compared to the best Conv-LSTM
model in terms of F1 score.
Interestingly, the MCC scores by all classifiers also show the pre-
diction was strongly correlated with the ground truth (measured
using a Pearson product-moment correlation coefficient we ob-
tained 0.70), probably because the embeddings generated by the
embedding methods are learnable quality drug features. The AUC
score generated by the Conv-LSTM network is found to be the high-
est, which is at least 3% better than the second-best score by the RF
classifier, where the LR classifier performed the worst. The ROC
curve in fig. 4 shows consistent AUC scores across the folds, which
signifies that the predictions are much better than random guessing.
4.2 Comparison of graph embedding methods
As seen in table 3, the classifiers work better with drug features
generated by the ComplEx, SimpleIE, and KGloVe methods. In par-
ticular, the GBT, RF, and Conv-LSTM classifiers perform consis-
tently best on the embeddings generated by ComplEx in terms of
F1, MCC, and AUPR scores. In contrast, using features generated
by the RDF2VEc method, we experience the worst DDIs predic-
tion accuracy. This is different from earlier work [8], where the
best results were obtained with RDF2Vec with uniform weighting
setting. We suspect that the classifiers did not benefit much from
more training samples in our case. Therefore, we validate this by
calibrating the best performing Conv-LSTM classifier against dif-
ferent embedding methods for which the output probability of the
classifier can be directly interpreted as a confidence level in terms of
‘fraction of positives’; the result is illustrated in fig. 5. As seen, the
Conv-LSTM classifier gave a probability value between 0.82 to 0.93,
which means 93% predictions belong to true positive predictions
generated by the embeddings from PBG.
Figure 5: Calibrating Conv-LSTM with embedding methods
4.3 Effects of number of drug samples
To understand the effects of having more training samples, and
to understand whether our classifiers suffer more from variance
errors or bias errors, we observed the learning curves of top-3
classifiers (i.e., RF, GBT, and Conv-LSTM) and SVM (a linear model)
for varying numbers of training samples. As shown in fig. 6, for
SVM the validation and training scores converge to a low value
with increasing size of the training set. Consequently, SVM did not
benefit much from more training samples. However, RF and GBT
are tree-based ensemble methods, and the Conv-LSTM network can
learn more complex concepts from the drug features. This results in
a lower bias, which can be observed fromhigher training scores than
the validation scores for the maximum number of drug samples,
i.e., adding more training samples does increase generalization.
4.4 Influence of negative samples
Inspired by [45], we investigated the influence of the number of
negatives per positive training sample, which we call σ , for Com-
plEx. As we already varied σ per training sample and set it to 15,
we further varied again the σ in [5, 10, 20, 25] and collected the
embeddings for each setting again. Then we observed if the Conv-
LSTM network performs better with the larger σ . Generating more
negatives samples moderately improves the results. In particular,
with 20 negative triples, we observed about 1% accuracy boost in
terms of AUPR. Embedding training also converged slightly faster.
Further increasing σ to 25 results in a drop in AUPR.
4.5 Comparison with state-of-the-art
Since our approach of data collection and preparation are different
from other approaches and we have more samples, a one-to-one
comparison was not viable –especially with Tiresias framework [1],
PRD[46], and INDI [17]. Kastrin et al. [24] used data from multiple
sources, but evaluated and inferred unknown DDIs from TWO-
SIDES only. With that dataset, they achieved the best AUPR score
of 0.93 using RF and GBT classifiers.
The Tiresias framework, which uses both pharmacological simi-
larities from embedding features, has reported an F1-score of 0.85
and AUPR of 0.92. Their pharmacological similarity features are
equivalent to INDI, which also uses the DrugBank v4.0 dataset.
INDI evaluated the performance of DDI prediction on a total of
37,212 true DDIs. They obtained AUC scores of 0.93 and an F1-score
of 0.89, omitting the interaction type (i.e., PD or PK) using a 10-fold
cross validation setting. Remzi et al. [8] observed an F1-score of
0.867 and AUPR of 0.918 using DrugBank v4.0 dataset.
With our approach, evaluations against several baseline models
yield an AUPR of up to 0.94, an F1-score of 0.92, and an MCC
of 0.80 during 5-fold cross-validation tests. This signifies that a
KG-based approach using multiple data sources is comparable to
current state-of-the-art methods. To show the benefit of using a
more robust classifier, we further trained the Conv-LSTM network
with DrugBank v4.0 dataset as shown in fig. 1. During a 5-fold
cross-validation test, we observed slightly better accuracy, namely
an F1-score of 0.895 and AUPR of 0.926, which outperforms [8].
5 CONCLUSION AND OUTLOOK
Adverse drug reactions are very dangerous and lead to a significant
number of the hospital (re-)admissions and even deaths. Many of
these reactions are due to drug-drug interactions. Preferably, all
drug-drug interactions should be known upfront to ensure that pre-
ventable cases do not occur. However, it is not feasible to investigate
all possible interactions, and hence approaches able to predict pos-
sible interactions are investigated. In this paper, we proposed the
use of knowledge graphs to integrate drug-related data from differ-
ent sources. This way, we have integrated background knowledge
about drugs, diseases, pathways, proteins, enzymes, chemical struc-
tures, etc. Since this background data is in a format which cannot
be used as a direct input for typical classifiers, we applied several
node embedding techniques to create a dense vector representation
for each node in the KG. These representations are then fed into
various traditional ML classifiers and a specifically designed neural
network architecture based on a convolutional-LSTM.
Our core observations are that i) We could outperform the base-
line classifiers, aswell as earlier state-of-the-artmodels, consistently
with our proposed architecture. We obtained up to 0.94, 0.92, 0.80
for AUPR, F1-score, and MCC, respectively, during 5-fold cross-
validation tests showing high confidence at predicting potential
DDIs. ii) From the embedding models we used, the PBG model did
perform best, but also SimpleE and KGloVe gave reasonable results.
One limitation of our approach is the inability to provide explana-
tions for the predicted DDIs. The embedding creates latent features,
which are like a black-box model. As future research directions, we
see i) the possibility to include even more data to the background.
For example, NDFRT, SemMedDB, and SIDE; also a large ablation
study to measure the influence of each of these additions would
be useful, ii) also including explicit information about negative
drug-drug interaction, as well as a prediction of the interaction
type, iii) providing explanations for the interactions, iv) further
investigation of other models to perform predictions on graphs,
and v) interaction with other (non-drug) substances like food.
(a) SVM (b) GBT
(c) RF (d) Conv-LSTM
Figure 6: Learning curves showing the validation and training scores of top-3 and SVM classifier
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